Summary of the contracting process

NHS England is in the planning stage for the procurement process titled "NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025". This tender falls under the pharmaceutical products industry category and is valued at approximately £1.52 billion (up to £1.82 billion gross). The procurement will occur in the United Kingdom and involves goods delivery. The contract period is set to start on 1 December 2025 and could extend until 31 May 2029 if renewal options are exercised. Interested suppliers must take note of the virtual 1:1 preliminary market engagement session that has been scheduled to be completed by 11 April 2025, with subsequent opportunities for questions to be submitted in writing within a 7-day window thereafter.

This procurement presents substantial business growth opportunities for suppliers in the pharmaceutical sector, particularly those specialising in medical retinal vascular treatments and related medicines. Businesses that are small and medium-sized enterprises (SMEs) could find this tender highly suitable, especially if they offer products such as anti-VEGF medications and intravitreal corticosteroids for conditions like macular degeneration and diabetic retinopathy. Companies engaged in the development and provision of such advanced medical treatments will find this tender an excellent opportunity to secure a significant NHS framework agreement, thereby expanding their market presence and contributing to essential healthcare services.

Planning

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

NHS ENGLAND

Contract Timeline

Publication Date

21st March 2025 08:54:22 AM

Planning Deadline

11th April 2025 22:59:59 PM Expired
Contract Summary

Provision of Medical Retinal Vascular Anti Veg-F and Intravitreal Corticosteroid medicines used in medical retinal vascular services for the NHS in England. To include but not limited to aflibercept, bevacizumab, brolucizumab, intravitreal dexamethasone, intravitreal fluocinolone, faricimab and ranibizumab used in the treatment of; • neovascular (wet) age-related macular degeneration (AMD) • visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) • proliferative diabetic retinopathy (PDR) • visual impairment due to diabetic macular oedema (DME) • visual impairment due to diabetic macular oedema (DME) who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy • vision impairment associated with chronic diabetic macular oedema, (DME) • visual impairment due to myopic choroidal neovascularisation (myopic CNV) • retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease • inflammation of the posterior segment of the eye presenting as non-infectious uveitis • prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye
Contract Details

Open Contracting ID

ocds-h6vhtk-04f70b

Publication Source

Find a Tender Service

Procurement Stage

Planning

Procurement Method

N/A

Procurement Method Details

N/A

Procurement Category

Goods

Tender Suitability

Framework / DPS

Framework
Contract Classification

CPV Code(s)

CPV Division(s)
Awarding Authority

NHS ENGLAND

Buyer Name

NHS England

Buyer Email

b.kullootee@nhs.net

Buyer Phone

Buyer Address

Wellington House, 133-135 Waterloo Rd

London

SE1 8UG

United Kingdom

View contract on Find a Tender Service

NHS National Framework for Medical Retinal Vascular Treatments - 1 December 2025

NHS ENGLAND

Contract Timeline

Contract Summary

Contract Details

Contract Classification

Awarding Authority